ABUS vs ESS
Arbutus Biopharma Corp (ABUS) versus Essex Property Trust Inc (ESS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Essex Property Trust Inc (ESS) is a reit - residential company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported ESS revenue for 2024-12-31 was $1.77B. Net income was $811.3M. Revenue was up 6.3% from 2023-12-31 to 2024-12-31. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
Not investment advice. Open the ABUS and ESS stock pages for the full models.
Not investment advice.